Budesonide is a Small Molecule owned by Orion, and is involved in 5 clinical trials, of which 4 were completed, and 1 is ongoing.

Budesonide binds to the glucocorticoid receptor and shows a wide range of inhibitory activities on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic and non-allergic-mediated inflammation. It binds to the glucocorticoid receptor (GR) and the drug-receptor complex translocates to the nucleus and acts as transcription factor for target gene expression. The antiinflammatory actions of budesonide are thought to involve phospholipase A2 inhibitory proteins such as the annexins (aka lipocortins), which control the biosynthesis of the major mediators of inflammation, prostaglandins and leukotrienes. Increased expression of the gene coding for annexin-1 is one of the mechanisms by which glucocorticoids inhibit inflammation.

The revenue for Budesonide is expected to reach a total of $4.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Budesonide NPV Report.

Budesonide is currently owned by Orion.

Budesonide Overview

Budesonide (Giona Easyhaler, Bufoler Easyhaler) is a corticosteroid derivative act as anti-asthmatic and an anti-inflammatory agent. It is formulated as powder for inhalation. It is indicated for the treatment of mild, moderate, and severe persistent asthma.

Orion Overview

Orion develops, manufactures and markets human and veterinary pharmaceuticals, and active pharmaceutical ingredients (APIs). Its products include pharmaceuticals for the treatment of central nervous system disorders, cancer, and respiratory diseases. The company’s pipeline encompasses investigational candidates for the treatment of amyotrophic lateral sclerosis, Parkinson’s disease, chronic obstructive pulmonary disease, and various cancer types. Orion’s client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics, and laboratories. The company sells its products in European markets through own sales network and in international markets through several partners and distributors. Orion is headquartered in Espoo, Finland.

The company reported revenues of (Euro) EUR1,041 million for the fiscal year ended December 2021 (FY2021), a decrease of 3.4% over FY2020. In FY2021, the company’s operating margin was 23.4%, compared to an operating margin of 26% in FY2020. In FY2021, the company recorded a net margin of 18.6%, compared to a net margin of 20.4% in FY2020. The company reported revenues of EUR491.8 million for the third quarter ended September 2022, an increase of 73.4% over the previous quarter.

Quick View – Budesonide

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Budesonide
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.